Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas D James

Showing results (81-90 of 198) with videos related to

Pageof 20
Sort By:
Oncotarget|June 5, 2018
Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratificationKym I E Snell, Douglas G Ward, Naheema S Gordon, et al.
European Urology|March 12, 2014
Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic reviewGuillaume Ploussard, Siamak Daneshmand, Jason A Efstathiou, et al.
JAMA Network Open|November 1, 2023
Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-AnalysisBrandon A Mahal, Lucia Kwak, Wanling Xie, et al.
The New England Journal of Medicine|October 8, 2004
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerIan F Tannock, Ronald de Wit, William R Berry, et al.
Journal of the National Cancer Institute|May 17, 2007
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)Malcolm D Mason, Matthew R Sydes, John Glaholm, et al.
European Urology Oncology|April 12, 2022
Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNADouglas G Ward, Laura Baxter, Sascha Ott, et al.
International Journal of Radiation Oncology, Biology, Physics|August 21, 2013
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004)Robert A Huddart, Emma Hall, Syed A Hussain, et al.
Clinical Epigenetics|August 12, 2025
Detection of genome-wide methylation changes in bladder cancer by long-read sequencing of urinary DNAAnshita Goel, Benjamin J Tura, Joanne D Stockton, et al.
European Urology Oncology|May 31, 2022
First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the LiteratureAdam B Weiner, Aisha L Siebert, Sarah E Fenton, et al.
JCO Global Oncology|November 14, 2024
Surgical Castration as an Alternative to Improve Systemic Treatment for Advanced Prostate Cancer: A Window of Opportunity for Developing CountriesFernando Sabino Marques Monteiro, Andre Deeke Sasse, Denizar Vianna Araujo, et al.
Pageof 20

Showing results (81-90 of 198) with videos related to

Sort By:
Pageof 20
Oncotarget|June 5, 2018
Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratificationKym I E Snell, Douglas G Ward, Naheema S Gordon, et al.
European Urology|March 12, 2014
Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic reviewGuillaume Ploussard, Siamak Daneshmand, Jason A Efstathiou, et al.
JAMA Network Open|November 1, 2023
Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-AnalysisBrandon A Mahal, Lucia Kwak, Wanling Xie, et al.
The New England Journal of Medicine|October 8, 2004
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerIan F Tannock, Ronald de Wit, William R Berry, et al.
Journal of the National Cancer Institute|May 17, 2007
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)Malcolm D Mason, Matthew R Sydes, John Glaholm, et al.
European Urology Oncology|April 12, 2022
Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNADouglas G Ward, Laura Baxter, Sascha Ott, et al.
International Journal of Radiation Oncology, Biology, Physics|August 21, 2013
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004)Robert A Huddart, Emma Hall, Syed A Hussain, et al.
Clinical Epigenetics|August 12, 2025
Detection of genome-wide methylation changes in bladder cancer by long-read sequencing of urinary DNAAnshita Goel, Benjamin J Tura, Joanne D Stockton, et al.
European Urology Oncology|May 31, 2022
First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the LiteratureAdam B Weiner, Aisha L Siebert, Sarah E Fenton, et al.
JCO Global Oncology|November 14, 2024
Surgical Castration as an Alternative to Improve Systemic Treatment for Advanced Prostate Cancer: A Window of Opportunity for Developing CountriesFernando Sabino Marques Monteiro, Andre Deeke Sasse, Denizar Vianna Araujo, et al.
Pageof 20